Prognostic value of cancer stem cell marker CD133 expression in gastric cancer: a systematic review

PLoS One. 2013;8(3):e59154. doi: 10.1371/journal.pone.0059154. Epub 2013 Mar 22.

Abstract

Objective: To investigate the correlation between CD133-positive gastric cancer and clinicopathological features and its impact on survival.

Methods: A search in the Medline and Chinese CNKI (up to 1 Dec 2011) was performed using the following keywords gastric cancer, CD133, AC133, prominin-1 etc. Electronic searches were supplemented by hand searching reference lists, abstracts and proceedings from meetings. Outcomes included overall survival and various clinicopathological features.

Results: A total of 773 gastric cancer patients from 7 studies were included. The median rate of CD133 expression by immunohistochemistry (IHC) was 44.8% (15.2%-57.4%) from 5 studies, and that by reverse transcription polymerase chain reaction (RT-PCR) was 91.3% (66.7%-100%) from 4 studies. The accumulative 5-year overall survival rates of CD133-positive and CD133-negative patients were 21.4% and 55.7%, respectively. Meta-analysis showed that CD133-positive patients had a significant worse 5-year overall survival compared to the negative ones (OR = 0.20, 95% CI 0.14-0.29, P<0.00001). With respect to clinicopathological features, CD133 overexpression by IHC method was closely correlated with tumor size, N stage, lymphatic/vascular infiltration, as well as TNM stage.

Conclusion: CD133-positive gastric cancer patients had worse prognosis, and was associated with common clinicopathological poor prognostic factors.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review
  • Systematic Review

MeSH terms

  • AC133 Antigen
  • Antigens, CD / metabolism*
  • Glycoproteins / metabolism*
  • Humans
  • Neoplastic Stem Cells / metabolism*
  • Peptides / metabolism*
  • Prognosis
  • Stomach Neoplasms / metabolism*
  • Stomach Neoplasms / pathology

Substances

  • AC133 Antigen
  • Antigens, CD
  • Glycoproteins
  • PROM1 protein, human
  • Peptides

Grants and funding

Domestic support from (1) National Natural Science Foundation of China (no. 81071777); (2) Outstanding Young Scientific Scholarship Foundation of Sichuan University, from the Fundamental Research Funds for the Central Universities of China (no. 2011SCU04B19); and (3) New Century Excellent Talents in University support program, Ministry of Education of China (2012SCU-NCET-11-0343). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.